Grants awarded Page

Transparency Portal Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure Access...

Contractes Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...

Economic and budgetary management Page

Transparency Portal Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure Access...

Dades i indicadors Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...

SOM Biotech identifies eravacycline as an effective treatment against SARS-CoV-2 Blog Post

The biopharmaceutical company SOM Biotech,based in the Barcelona Science Park, announces the preclinical validation studies of eravacycline as an effective treatment against SARS-CoV-2. The conclusions of the studies will be presented at the virtual event IDWeek 2020. that will be held from October 21 to 25. Eravacycline is one of the three drugs that the company has identified and validated in collaboration with Ewha Womans University for the treatment of the new coronavirus, and SOM already plans to carry out a Phase 2 clinical trial.

 

 

Moirai Biodesign developes a diagnostic kit for the detection of sepsis in three hours Blog Post

Moirai Biodesign, a biotech start-up based in the Barcelona Science Park, has developed a prototype ‘kit’ based on biosensors that analyzes a blood sample and identifiesthe most important sepsis-causing pathogens and their associated antibiotic resistances, at the point of care and directly from the patient’s blood, in just three hours, a process that usually requires up to 5 days of analysis in the laboratory. The company has just received a €75,000 grant through the Startup Capital financing line from ACCIÓ to  to set about the activities derived from the execution of the initial business plan. Its objective is to market this device in hospitals, once the validation phase is completed.The kit will allow identification 

Researchers discover the adhesion mechanism of the bacterium that causes 40% of atypical pneumonias Blog Post

Researchers from Institute of Molecular Biology of Barcelona (IBMB-CSIC) –based in the Barcelona Science Park– and the Institute for Natural Science and Technology at the University of Osaka, has succeeded in determining the three-dimensional structure of proteins by means of which the bacteria Mycoplasma pneumoniae –that cause 40% of atypical pneumonias– attaches itself to human cells and initiates infection. From the structure, this team of scientists have designed antibodies that decrease this adhesion capacity and opens the door to develop new therapies and vaccines against this pathogen.

 

Ernest Giralt, first IRB Barcelona Emeritus Professor Blog Post

Ernest Giralt Lledó is retiring after 15 years at the Institute for Research in Biomedicine (IRB Barcelona), where he has played a key institutional and scientific role. Dr Giralt, today an international reference for science of excellence, will continue to be linked to Institute as an Emeritus Professor. This appointment will allow him to share his guidance and expertise with the current community of scientists.

 

Scott Boyer joins Chemotargets as new CEO Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, has appointed Dr. Scott Boyer as new CEO. He takes over from Dr. Jordi Mestres, who becomes Chief Scientific Officer and will maintain his position as President of the Board. With the new incorporation, the company, based in the Barcelona Science Park, consolidates its transition from a software business to an AI-driven biotech company.

 

La Fundació PCB Page

Portal de Transparència Active advertising Institutional information Economic, budgetary and asset management Contracts and agreements List of companies to which the foundation subcontracts services Grants awarded Staff Content update procedure...